Market Place
Sourcing Support
Aptose Reports Results for the Q3 2024
08 Nov 2024 //
GLOBENEWSWIRE
Aptose Announces Results from Special Meeting of Shareholders
05 Sep 2024 //
GLOBENEWSWIRE
Aptose Receives $10M From Hanmi; Negotiating Future Collaboration
30 Aug 2024 //
GLOBENEWSWIRE
Aptose Announces Adjournment of its Special Meeting of Shareholders
15 Aug 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2024
08 Aug 2024 //
GLOBENEWSWIRE
Aptose Announces Receipt of Deficiency Notice from Nasdaq
19 Jul 2024 //
GLOBENEWSWIRE
Aptose Announces Results from Annual and Special Meeting of Shareholders
18 Jun 2024 //
GLOBENEWSWIRE
Aptose Presents Tuspetinib Findings At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Aptose Closes $4.43M At-The-Market Registered Direct Offering
03 Jun 2024 //
GLOBENEWSWIRE
Aptose Announces $4.43M Direct Offering Per Nasdaq Rules
31 May 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the First Quarter 2024
14 May 2024 //
GLOBENEWSWIRE
Aptose To Report Q1 2024 Results, Clinical Strategy On May 14
06 May 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 2024 //
GLOBENEWSWIRE
Aptose to Report Fourth Quarter & Year End 2023 Financial Results & Provid
18 Mar 2024 //
GLOBENEWSWIRE
Aptose to Report Fourth Quarter and Year End 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Aptose Announces Closing of $9.7 Million Public Offering
31 Jan 2024 //
GLOBENEWSWIRE
Aptose Announces Pricing of $8.4 Million Public Offering
26 Jan 2024 //
GLOBENEWSWIRE
Aptose Tuspetinib Data Featured in Oral Presentation
09 Dec 2023 //
GLOBENEWSWIRE
Aptose Appoints Fletcher Payne Chief Business Officer
30 Nov 2023 //
GLOBENEWSWIRE
Aptose Reports Results for the Third Quarter 2023
09 Nov 2023 //
GLOBENEWSWIRE
Aptose Tuspetinib Clinical Data Selected for Presentation at the 2023 ASH
02 Nov 2023 //
GLOBENEWSWIRE
Aptose Presents Highlights from Webcast Featuring Data on AML Drug Tuspetinib
30 Oct 2023 //
GLOBENEWSWIRE
Aptose to Report Third Quarter 2023 Financial Results
26 Oct 2023 //
GLOBENEWSWIRE
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib
23 Oct 2023 //
GLOBENEWSWIRE
Aptose Data to be Presented at ESH 6th International Conference
16 Oct 2023 //
GLOBENEWSWIRE
Aptose to Present at the Cantor Global Healthcare Conference
18 Sep 2023 //
GLOBENEWSWIRE
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
06 Sep 2023 //
GLOBENEWSWIRE
Aptose to Present at H.C. Wainwright 25th Annual Global Investment Conference
24 Aug 2023 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2023
10 Aug 2023 //
GLOBENEWSWIRE
Aptose to Report Second Quarter 2023 Financial Results
27 Jul 2023 //
GLOBENEWSWIRE
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
26 Jun 2023 //
GLOBENEWSWIRE
Aptose Presents Highlights from Clinical Update
10 Jun 2023 //
GLOBENEWSWIRE
Aptose Biosciences Provides Update on Reverse Stock Split
05 Jun 2023 //
GLOBENEWSWIRE
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
31 May 2023 //
GLOBENEWSWIRE
Aptose Enters into $25 Million Committed Equity Facility
25 May 2023 //
GLOBENEWSWIRE
Aptose Announces Results of Annual and Special Meeting of Shareholders
23 May 2023 //
GLOBENEWSWIRE
Aptose Reports Results for the First Quarter 2023
08 May 2023 //
GLOBENEWSWIRE
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
04 May 2023 //
GLOBENEWSWIRE
Aptose to Report 1Q 2023 FYR and Hold Conference Call on Monday, May 8, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Aptose to Participate in Canaccord Genuity 2023 Horizons in Oncology Conference
10 Apr 2023 //
GLOBENEWSWIRE
Aptose to Participate in Cantor The Future of Oncology Virtual Symposium
28 Mar 2023 //
GLOBENEWSWIRE
Aptose Reports Results for the Fourth Quarter and Full Year 2022
23 Mar 2023 //
GLOBENEWSWIRE
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
10 Mar 2023 //
GLOBENEWSWIRE
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
02 Mar 2023 //
GLOBENEWSWIRE
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial
30 Jan 2023 //
GLOBENEWSWIRE
Aptose Biosciences Establishes New At-The-Market Facility
12 Dec 2022 //
GLOBENEWSWIRE
Aptose Announces Updated Responses Across Four Dose Levels of Tuspetinib
11 Dec 2022 //
GLOBENEWSWIRE
Aptose to Hold Clinical Update and Data Review of AML Drug TuspetinibÂ
07 Dec 2022 //
GLOBENEWSWIRE
Aptose Treats First Patient with Dosing of New “G3” Formulation Luxeptinib
14 Nov 2022 //
GLOBENEWSWIRE
Aptose to Report Third Quarter 2022 Financial Results
18 Oct 2022 //
GLOBENEWSWIRE
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
12 Sep 2022 //
GLOBENEWSWIRE
Aptose to Present at H.C. Wainwright 24th Annual Global Investment Conference
30 Aug 2022 //
GLOBENEWSWIRE
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
27 Jul 2022 //
GLOBENEWSWIRE
Aptose to Report Q2 2022 Financial Results
19 Jul 2022 //
GLOBENEWSWIRE
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
27 Jun 2022 //
GLOBENEWSWIRE
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
02 Jun 2022 //
GLOBENEWSWIRE
Aptose Presents Highlights from Corporate Update and KOL Event
02 Jun 2022 //
GLOBENEWSWIRE
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
31 May 2022 //
GLOBENEWSWIRE
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
25 May 2022 //
GLOBENEWSWIRE
